利妥昔单抗治疗大疱性类天疱疮:20例回顾性研究
该单中心回顾性研究纳入20例接受至少1剂利妥昔单抗治疗的大疱性类天疱疮患者,其中75%(n=15)在平均169天后达到缓解,无利妥昔单抗相关死亡且不良事件显著减少,提示利妥昔单抗对重症或难治性BP具有较高缓解率、激素节省效应和可接受的安全性。
要点
- 利妥昔单抗治疗后75%患者(n=15)达到缓解,平均缓解时间169天。
- 未观察到利妥昔单抗相关死亡,治疗后不良事件显著减少。
- 利妥昔单抗可用于重症BP初始治疗或传统免疫治疗失败后的难治性病例。
核心结论
- 利妥昔单抗在重症或传统治疗难治性大疱性类天疱疮患者中显示出高缓解率、激素节省效应和可接受的安全性。
研究设计与样本
- 单中心回顾性病历 review,纳入20例接受至少1剂利妥昔单抗治疗的大疱性类天疱疮患者。
主要发现
- 75%患者(n=15)在利妥昔单抗治疗后平均169天达到缓解。
- 无利妥昔单抗相关死亡,且利妥昔单抗治疗后不良事件显著减少。
临床怎么用
- 对于重症大疱性类天疱疮或传统免疫治疗失败的患者,可考虑使用利妥昔单抗治疗。
局限性
- 研究为回顾性设计,仅限单中心,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune blistering disease requiring treatment with immunosuppressive medications; however, finding a therapy that has a sustained durable response and an acceptable side effect profile has been challenging. OBJECTIVE: Our study aimed to evaluate the clinical outcomes of patients with BP treated with rituximab therapy at a single academic center. METHODS: A retrospective chart review was performed on 20 patients who received at least 1 dose of rituximab therapy, either as initial therapy for severe BP or as therapy for recalcitrant disease after having failed conventional immunotherapies. RESULTS: Within our cohort, 75% of patients (n = 15) achieved remission an average of 169 days following rituximab therapy. There were no rituximab-related deaths and significantly fewer adverse events following rituximab therapy. LIMITATIONS: This study was limited by its retrospective nature, focus on a single academic center, and small sample size. CONCLUSION: Use of rituximab therapy demonstrated high rates of remission, steroid-sparing activity, and an acceptable safety profile in our cohort of patients with severe BP or disease refractory to conventional therapies.
引用
- Polansky M, Eisenstadt R, DeGrazia T, et al. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. J Am Acad Dermatol. 2019. PMID: 30923002. doi:10.1016/j.jaad.2019.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。